Tanja Obradovic: Even rougher times ahead for Biotech?
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn:
“Even rougher times ahead for Biotech?
The SPDR Biotech ETF index (XBI) dropping for a month about 14 % (in comparison Nasdaq during same period down about 8%) while weathering recent trading policy changes and general volatility.
XBI is at approximately half its 2021 peak. Nearly 30% of U.S.-listed small- and mid-cap Biotechs are trading at or below cash, suggesting the market does not see any value to their existing business or drug development pipeline. While general business environment is something to swim in, action on the pipeline strategy to strengthen business reasoning as well as decision-making process rather than undertaking low probability of success or marginal products into development is gaining importance.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023